Apaziquone

(for Intravesical Instillation)

Apaziquone is an investigational drug not yet approved by the FDA.


Apaziquone is a bioreductive agent activated by reductase enzymes, such as DT-diaphorase, expressed by bladder tumor cells, to form cytotoxic alkylating agents.

> To read about the latest news about apaziquone, or to learn more about its current development, click here.

Apaziquone is being investigated for intravesical instillation post-transurethral resection of bladder tumors (post-TURBT) in patients with non-muscle invasive bladder cancer (NMIBC).

Apaziquone is an investigational drug not yet approved by the FDA.

More About Apaziquone

Development Indications

Apaziquone is being investigated for intravesical instillation post-transurethral resection of bladder tumors
(post-TURBT) in patients with non-muscle invasive bladder cancer (NMIBC).

Latest News on Apaziquone